The weighted share price index of Taiwan Stock Exchange opened 0.2% lower at 23,002.37.The weighted share price index of Taiwan Stock Exchange opened 0.2% lower at 23,002.37.Japan's Topix index fell to 1%.
Treasury bond futures opened, with 30-year main contracts rising by 0.48%, 10-year main contracts rising by 0.36%, 5-year main contracts rising by 0.25% and 2-year main contracts rising by 0.05%.The main contract of the container transport index (European line) rose by 150.2 points in the day, and now it is reported at 2567.8 points, an increase of 6.21%.Solar energy and other new companies have set up photovoltaic power generation equipment business. The enterprise search APP shows that recently, China Energy Saving Ledebao Solar Technology (Delingha) Co., Ltd. was established, with Du Hu as the legal representative and a registered capital of 1 million yuan. Its business scope includes: sales of solar thermal utilization equipment; Lease of photovoltaic power generation equipment; Ecological restoration and ecological protection services, etc. Enterprise investigation shows that the company is jointly owned by China Energy Saving Solar Technology Co., Ltd. and Qinghai Laidebao New Materials Co., Ltd., a wholly-owned subsidiary of solar energy.
Kangxinuo said on the interactive platform that the company is promoting the research and development of a variety of innovative vaccines, submitting applications for related matters in accordance with the guiding principles of CDE, and actively communicating and reporting.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)Black Myth: Wukong won the best action game of the year by TGA.